“…We aimed at investigating whether the association with and the ability to predict all-cause mortality in the general population of a 14-metabolite score (14-MS), 8 also known as MetaboHealth, is confirmed in type 2 diabetes. We also investigated whether these metabolites can be used to improve well-established and wellperforming mortality prediction models of all-cause mortality in type 2 diabetes: Estimation of Mortality Risk in Type 2 Diabetic Patients (ENFORCE), an user-friendly and freely available risk 9variable algorithm, which has been validated in several different context, 7,[9][10][11] and Risk Equations for Complications of Type 2 Diabetes (RECODe), a 14-variable algorithm also validated in many distinct cohorts derived from both trial and population-based studies. 12,13 To this aim, the Nightingale Health's metabolomics technology, which is widely exploited in people with type 2 diabetes, [14][15][16] was used.…”